Analystreport

Turning Point Therapeutics (NASDAQ: TPTX) is now covered by analysts at Leerink Swann. They set an "outperform" rating and a $42.00 price target on the stock.

Turning Point Therapeutics, Inc. - Common stock  (TPTX) 
Last turning point therapeutics, inc. - common stock earnings: 3/16 09:00 am Check Earnings Report